Compass Pathways reports durable depression trial data

• Compass Pathways (NASDAQ:CMPS) announced positive 26-week data from its Phase 3 COMP006 clinical trial evaluating its proprietary synthetic psilocybin formulation, COMP360.
• The findings show that nearly 40% of chronic treatment-resistant depression patients maintained a clinically meaningful response six months after receiving two fixed doses.
• The company is currently advancing a rolling regulatory submission with the FDA and remains on track to finalize the marketing application by late 2026.

Compass Pathways (NASDAQ:CMPS) announced Phase 3 clinical trial results demonstrating that its proprietary synthetic psilocybin compound, COMP360, provides durable therapeutic relief for treatment-resistant depression.

The clinical program evaluated nearly 600 individuals suffering from chronic depressive episodes that lasted on average for more than three years.

"COMP360 has demonstrated rapid, durable and reproducible clinical effects through at least six months — with a consistent safety profile — across two large, well-controlled Phase 3 studies," said Compass Pathways Chief Medical Officer Doctor Guy Goodwin.

The updated findings revealed that 39% of participants in the 25 mg cohort achieved a significant, long-lasting reduction in baseline depression severity scales through week 26.

The London-based biotechnology corporation specializes in developing evidence-based psychedelic medicine platforms to transform standard mental health care models for underserved populations.

The drug developer expects to complete its final New Drug Application submission during the fourth quarter of 2026 to prepare for an anticipated commercial launch in early 2027.